Seikagaku Of Japan Applies For Additional Indication Of Hyaluronate In U.S.
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Seikagaku submitted an application Sep. 28 for an additional indication of pain associated with shoulder osteoarthritis for Supartz (hyaluronate) with U.S. FDA